Change in Allergy Practice during the COVID-19 Pandemic

Basit Öğe Kaydı
dc.contributor.authorOzturk, Ayse Bilge
dc.contributor.authorBaccioglu, Ayse
dc.contributor.authorSoyer, Ozge
dc.contributor.authorCivelek, Ersoy
dc.contributor.authorSekerel, Bulent Enis
dc.contributor.authorBavbek, Sevim
dc.date.accessioned2025-01-21T16:36:30Z
dc.date.available2025-01-21T16:36:30Z
dc.date.issued2021
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground: International guidelines in asthma and allergy has been updated for COVID-19 pandemic and pandemic has caused dramatic changes in allergy and immunology services. However, it is not known whether specialty-specific recommendations for COVID-19 are followed by allergists. Objectives: By conducting this study, we aimed to determine the attitudes and experiences of adult/pediatric allergists on allergy management during COVID-19. Method: We used a 20-question survey to elicit data from allergists (residents and pediatric and adult allergists registered to the Turkish National Society of Allergy and Clinical Immunology) across Turkey via e-mail. We analyzed the data statistically for frequency distributions and descriptive analysis. Results: A total of 183 allergists participated in the survey. Telemedicine was used for management of asthma (73%), allergic rhinitis (53%), atopic dermatitis (51%), chronic urticaria/angioedema (59%), drug hypersensitivity (45%), food allergy (48%), venom allergy (30%), anaphylaxis (22%), and hereditary angioedema (28%). Thirty-one percent of the respondents discontinued subcutaneous immunotherapy (SCIT) during the COVID-19 pandemic. Thirty-four percent of the physicians reported interruption of systemic steroid use in asthma patients, and 25% of the respondents discontinued biological therapy. Conclusions: Allergists in Turkey have been using telemedicine at a high rate during the COVID-19 pandemic for asthma and rhinitis. The continuation rate of SCIT was low while the discontinuation rate of biologicals and systemic steroid use in asthma was high in Turkey.Our study results and learning from the experiences of other countries and specialties may help to optimize allergy practice and compatibility with international guidelines. (C) 2020 S. Karger AG, Basel
dc.identifier.doi10.1159/000512079
dc.identifier.endpage52
dc.identifier.issn1018-2438
dc.identifier.issn1423-0097
dc.identifier.issue1
dc.identifier.pmid33059353
dc.identifier.startpage49
dc.identifier.urihttps://doi.org/10.1159/000512079
dc.identifier.urihttps://hdl.handle.net/20.500.12587/24315
dc.identifier.volume182
dc.identifier.wosWOS:000605445900006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofInternational Archives of Allergy and Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectAllergy; Allergic disease; Allergic asthma; Allergy and immunology; COVID-19
dc.titleChange in Allergy Practice during the COVID-19 Pandemic
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu